Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Fish and Richardson

Generated: September 25, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 9,149,532 protect, and when does it expire?

Patent ► Subscribe protects SAVAYSA and is included in one NDA.

This patent has twenty-six patent family members in eighteen countries.

Summary for Patent: ► Subscribe

Title:Pharmaceutical composition
Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N.sup.1-(5-chloropyridin-2-yl)-N.sup.2-((1S,2R,4S)-4-[(dimethylamino)carb- onyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl- ]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive. ##STR00001##
Inventor(s): Kojima; Masazumi (Shinagawa-ku, JP), Kuno; Yoshio (Shinagawa-ku, JP), Nakagami; Hiroaki (Shinagawa-ku, JP), Sagasaki; Shinji (Shimada, JP), Ishidoh; Koichi (Hiratsuka, JP), Sekiguchi; Gaku (Hiratsuka, JP)
Assignee: Daiichi Sanykyo Company, Limited (Tokyo, JP)
Application Number:13/968,776
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Daiichi Sankyo Inc
edoxaban tosylate
TABLET;ORAL206316-001Jan 8, 2015RXYesNo► Subscribe► SubscribeY
Daiichi Sankyo Inc
edoxaban tosylate
TABLET;ORAL206316-002Jan 8, 2015RXYesNo► Subscribe► SubscribeY
Daiichi Sankyo Inc
edoxaban tosylate
TABLET;ORAL206316-003Jan 8, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-087327Mar 29, 2007

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2008241982► Subscribe
BrazilPI0809205► Subscribe
Canada2680039► Subscribe
China101652139► Subscribe
China104324015► Subscribe
Colombia6220955► Subscribe
European Patent Office2140867► Subscribe
Israel200790► Subscribe
Israel219829► Subscribe
Japan2010090168► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus